Structure Therapeutics Inc. (NASDAQ: STRC) CEO Michael Stevens unveiled a revised development roadmap focused on advancing two lead candidates into pivotal trials by 2027, with $185 million in planned R&D investment over the next three years. The company also announced a strategic collaboration with a mid-sized biotech to accelerate delivery platform integration.
- Structure Therapeutics Inc. (NASDAQ: STRC) plans $185 million in R&D investment from 2026–2028
- STRC-204 and STRC-301 expected to enter Phase 3 trials by mid-2027
- STRC-204 achieved 47% LDL cholesterol reduction in Phase 2 cohort of 98 patients
- STRC-301 maintained stable lung function in 62% of patients at 24 months
- Strategic collaboration with undisclosed biotech to enhance delivery platform technology
- STRC shares rose 12% in pre-market trading post-announcement
Structure Therapeutics Inc. (NASDAQ: STRC) has intensified its clinical development focus, with CEO Michael Stevens announcing a targeted expansion of its pipeline portfolio centered on two proprietary RNA-based therapeutics. The strategy aims to advance both STRC-204 and STRC-301 into Phase 3 trials by mid-2027, following positive Phase 2 data for STRC-204 in patients with familial hypercholesterolemia. The company plans to allocate $185 million in research and development funding from 2026 through 2028 to support these efforts and enhance internal manufacturing capabilities. The revised pipeline approach reflects a shift toward prioritizing assets with near-term regulatory potential. STRC-204 demonstrated a 47% reduction in LDL cholesterol levels at 12 weeks in a cohort of 98 patients, while STRC-301 showed durable responses in a rare pulmonary fibrosis cohort, with 62% of participants maintaining stable lung function at 24 months. These benchmarks are central to the company’s goal of securing accelerated approval pathways in the U.S. and EU by 2028. Market impact is already evident: STRC shares rose 12% in pre-market trading following the announcement, driven by investor confidence in the company's ability to de-risk its development path. The partnership with a privately held biotechnology firm—whose identity remains undisclosed—will integrate a lipid nanoparticle delivery system optimized for tissue-specific targeting, potentially improving bioavailability and reducing dosing frequency for future candidates. Stevens emphasized that the updated strategy balances innovation with operational discipline, stating that decisions were guided by clinical efficacy, regulatory feasibility, and commercial scalability. With the expanded pipeline now including three additional early-stage programs in oncology and neurodegeneration, Structure Therapeutics positions itself as a mid-tier player capable of executing complex development timelines under constrained capital conditions.